Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267

1.

Expansion of human regulatory T-cells from patients with type 1 diabetes.

Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA.

Diabetes. 2009 Mar;58(3):652-62. doi: 10.2337/db08-1168. Epub 2008 Dec 15.

2.

Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.

Ukena SN, Höpting M, Velaga S, Ivanyi P, Grosse J, Baron U, Ganser A, Franzke A.

Exp Hematol. 2011 Dec;39(12):1152-60. doi: 10.1016/j.exphem.2011.08.010. Epub 2011 Aug 22.

PMID:
21864487
3.

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH.

Diabetes. 2010 Feb;59(2):407-15. doi: 10.2337/db09-0694. Epub 2009 Oct 29.

4.

Mesenchymal cells recruit and regulate T regulatory cells.

Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, Sportoletti P, Falzetti F, Tabilio A.

Exp Hematol. 2008 Mar;36(3):309-18. doi: 10.1016/j.exphem.2007.11.007.

PMID:
18279718
5.

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM.

J Immunol. 2011 Apr 1;186(7):3918-26. doi: 10.4049/jimmunol.1003099. Epub 2011 Mar 2.

6.

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.

Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM.

Gut. 2016 Apr;65(4):584-94. doi: 10.1136/gutjnl-2014-306919. Epub 2015 Feb 24.

7.

Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.

Sobel ES, Brusko TM, Butfiloski EJ, Hou W, Li S, Cuda CM, Abid AN, Reeves WH, Morel L.

Arthritis Res Ther. 2011 Jun 27;13(3):R106. doi: 10.1186/ar3387.

8.

Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.

Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM, Bonagura VR.

Clin Cancer Res. 2012 Apr 1;18(7):1925-35. doi: 10.1158/1078-0432.CCR-11-2941. Epub 2012 Feb 9.

9.

The effector T cell response to ryegrass pollen is counterregulated by simultaneous induction of regulatory T cells.

Mittag D, Scholzen A, Varese N, Baxter L, Paukovics G, Harrison LC, Rolland JM, O'Hehir RE.

J Immunol. 2010 May 1;184(9):4708-16. doi: 10.4049/jimmunol.0901036. Epub 2010 Mar 22.

10.

Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.

Singh M, Basu S, Camell C, Couturier J, Nudelman RJ, Medina MA, Rodgers JR, Lewis DE.

Eur J Immunol. 2008 Jun;38(6):1522-32. doi: 10.1002/eji.200737929.

11.

Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro.

Singh AK, Horvath KA, Mohiuddin MM.

Transplant Proc. 2009 Jan-Feb;41(1):418-21. doi: 10.1016/j.transproceed.2008.10.079.

12.

Impact of culture medium on CD4(+) CD25(high)CD127(lo/neg) Treg expansion for the purpose of clinical application.

Gołąb K, Krzystyniak A, Marek-Trzonkowska N, Misawa R, Wang LJ, Wang X, Cochet O, Tibudan M, Langa P, Millis JM, Trzonkowski P, Witkowski P.

Int Immunopharmacol. 2013 Jul;16(3):358-63. doi: 10.1016/j.intimp.2013.02.016. Epub 2013 Mar 4.

PMID:
23466550
14.

Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.

Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A.

Cytotherapy. 2007;9(2):144-57.

PMID:
17453966
15.

Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes.

Aghili B, Amirzargar AA, Rajab A, Rabbani A, Sotoudeh A, Assadiasl S, Larijani B, Massoud A.

Iran J Immunol. 2015 Dec;12(4):240-51. doi: IJIv12i4A2.

16.

Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.

Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG.

J Immunol. 2006 Dec 15;177(12):8338-47.

17.

CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression.

Arroyo Hornero R, Betts GJ, Sawitzki B, Vogt K, Harden PN, Wood KJ.

Transplantation. 2017 Feb;101(2):302-309. doi: 10.1097/TP.0000000000001278.

19.

Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells.

Di Caro V, D'Anneo A, Phillips B, Engman C, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N.

Clin Exp Immunol. 2011 Jul;165(1):60-76. doi: 10.1111/j.1365-2249.2011.04334.x. Epub 2011 Mar 17.

20.

Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.

Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M.

Blood. 2006 Dec 15;108(13):4260-7. Epub 2006 Aug 17.

Supplemental Content

Support Center